



Quantifying Risk, Enabling Opportunity.

Demystifying the Iterative Risk Margin

Author: Yura Kaliazin, Charl du Plessis (Deloitte)

Date: 9 June 2020

AGENDA

- INTRODUCTION
- MOVIE RECOMMENDATION
- SOME THEORY
- IRM MYTHBUSTERS
- IN CONCLUSION...
- QUESTIONS





INTRODUCTION



ITERATIVE RISK MARGIN???




What do these two pictures have in common?



What do these two pictures have in common?



What is the (Iterative) Risk Margin?




- SAM uses a simplification whereby change in RM is ignored

$$\text{SCR shock} = \Delta \text{BEL} - \Delta \text{Assets}$$


- Theoretically correct approach introduces circularity

$$\text{SCR shock} = \Delta \text{BEL} + \Delta \text{RM} - \Delta \text{Assets}$$

An example



An example...cont'd



How does the calculation work?

1

$$\begin{aligned} \text{SCR shock } x &= \Delta BEL + \Delta RM - \Delta Assets \\ &= \Delta BEL + (RM_{\text{new}} - RM_{\text{prev}}) - \Delta Assets \end{aligned}$$

2

$$= CoC * \sum_{t=0}^{\infty} (NH \text{ SCR} | \text{shock } x)_t * v^t$$

3

SCR shock 1 | shock x @ t
SCR shock 2 | shock x @ t
...

How does the calculation work? Cont'd

4

$$\begin{aligned} \text{SCR shock 1} \mid \text{shock } x @ t &= [\Delta BEL \mid \text{shock } x + \Delta RM \mid \text{shock } x - \Delta Assets \mid \text{shock } x] @ t \\ &= [(\Delta BEL - \Delta Assets) \mid \text{shock } x] @ t + [\Delta RM \mid \text{shock } x] @ t \end{aligned}$$

Shock within shock: estimated based on the “|shock x” proxies


Result from previous iteration; or zero for the initial iteration

To proxy or not to proxy?




- **Total run time** would be significant for an exhaustive set of model runs.
- Full model run needed for **every “shock upon shock” combination**.
- Hence, the need for proxies to estimate:
 - **Projected SCRs** using **projected proxy**
 - **Re-calculated SCRs** in a “shock upon shock” using **shocked proxy**

When is convergence achieved?



- The **process is repeated** until the values of the **SCR** and **Risk Margin converge**
 - I.e. when the **successive difference** from one iteration to the next becomes **immaterial**
- Typically there may be about **10 to 20 iterations**

How significant is it?



- It **depends** on:
 - **Mass lapse** risk and its run-off
 - **Mix** of risks
 - **Relative run-off** of risks
- **Range** of impacts possible depending on the above factors
- Reductions in **both SCR** and **Risk Margin** are typically in the **10% - 30%** range.




IRM MYTH BUSTERS




Myth 1: You need big IT/systems to perform IRM

- Although you need to do a significant number of runs to **test your proxies**, these can be done in the valuation '**off-season**'.
- Iterative calculation process can be implemented in a **macro-based Excel model** to perform the Risk Margin and SCR recalculations for each iteration till convergence



Myth 2: Market risk stresses are unaffected by the IRM

- For a **total balance sheet approach**, stresses must be calculated based on the change in TPs, **including the Risk Margin**.
 - $\text{SCR shock} = \Delta\text{TP} - \Delta\text{Assets} = (\Delta\text{BEL} + \Delta\text{RM}) - \Delta\text{Assets}$
- Under certain market risk stresses (and for certain products), a material change in RM may arise due to a change in:
 - **Non-hedgeable exposure** as a second-order effect
 - **Yield curve** for discounting



Myth 3: Using IRM always improves your SAM solvency

There are instances where using the IRM could have a **negative impact** on the solvency position. This is generally the case for products with **positive rand reserves**. Consider the following examples:

- **Non profit annuity** with its **longevity risk**
- A **risk policy** that is no longer in a profitable position (i.e. with a positive BEL). We need to consider both the **lapse (down) shock** and **mortality direction**



Quantifying Risk, Enabling Opportunity.

Myth 4: You can cherry-pick products for the IRM

- Given that the IRM does not always result in a benefit, it is **not advisable** for companies to cherry pick the products.
- Consider the possibility of having to perform the IRM for **all products** when ultimately seeking approval for the method
- **Simplified models** for other product lines so that the revised IRM reflects an accurate picture for the total business



Myth 5: The application process is quick and simple

- Application form requires applicants to demonstrate a **deep understanding** of:
 - Iterative methodology and approach
 - Use of proxies and any other simplifying assumptions
 - Controls and documentation
- Furthermore, the IRM methodology and calculation models must be **independently reviewed** by the HAF and the auditors.




Myth 6: The IRM concept doesn't apply outside of SAM

- **EV** via your **Required Capital** and **CoC** calculations (or **CNHR** for MCEV) depending on how these measures are defined for your business
- **IFRS 17 Risk Adjustment**, the magnitude of the Risk Adjustment could depend significantly on whether **IRM approach** is used
- **Internal Capital models**




IN CLOSING...

- IRM is **not that scary!**
- You don't need **NASA servers** to do it
- It's **not a silver bullet** for every insurer
- IRM is **usable** outside of SAM
- Yes, the **approval process** is not easy...



QUESTIONS?



Contact details



Yura Kaliazin

Associate Director AIS

ykaliazin@deloitte.co.za

+27 (0)21 427 5354

+27 (0)83 368 0198



Charl du Plessis

Assistant Manager AIS

charduplessis@deloitte.co.za

+27 (0)21 427 5598

+27 (0)79 343 3544